New therapies for diabetic kidney disease

New England Journal of Medicine

Volumn 369, Issue 26, 2013, Pages 2549-2550

  Himmelfarb, Jonathan ^a   Tuttle, Katherine R ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SACRED HEART MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT INHIBITOR; ALDOSE REDUCTASE INHIBITOR; ANTIFIBROTIC AGENT; BARDOXOLONE METHYL; PROTEIN KINASE C INHIBITOR; SULODEXIDE; UNCLASSIFIED DRUG;

CLINICAL RESEARCH; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE SEVERITY; EDITORIAL; END STAGE RENAL DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; MORTALITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; TREATMENT FAILURE;

EID: 84890961378     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1313104     Document Type: Editorial

References (10)

1. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24:302-8.
2. Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-8.
3. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850-86. [Erratum, Am J Kidney Dis 2013;61:1049.]
4. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-9.
5. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
6. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.
7. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327-36.
8. de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013;369:2492-503.
9. Zoja C, Corna D, Nava V, et al. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol 2013;304:F808-19.
10. Collins FS. Reengineering translational science: the time is right. Sci Transl Med 2011;3:90 cm17.